Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Ventricular tachycardia (VT) and ventricular fibrillation (VF) pose significant challenges for patients with implantable cardioverter-defibrillators (ICDs).
• Identifying effective pharmacological interventions to manage these arrhythmias in ICD patients is crucial for improving outcomes.

Purpose of the Study:

• To evaluate the efficacy of ranolazine in reducing the incidence of VT, VF, or death in high-risk patients with ICDs.
• To assess the impact of ranolazine on secondary endpoints, including ICD shocks and recurrent ventricular arrhythmias.

Main Methods:

• A double-blind, placebo-controlled trial randomized 1,012 high-risk ICD patients with cardiomyopathy to receive either 1,000 mg of ranolazine twice daily or a placebo.
• The primary endpoint was the first occurrence of VT/VF requiring appropriate ICD therapy or death.
• Secondary endpoints included ICD shocks, recurrent VT/VF, and other clinical outcomes.

Main Results:

• Ranolazine did not significantly reduce the primary endpoint (VT, VF, or death) compared to placebo (HR 0.84, p=0.117).
• The study was underpowered to detect a significant difference in the primary endpoint.
• Ranolazine was associated with a marginally significant reduction in recurrent VT or VF requiring ICD therapy (HR 0.70, p=0.028).

Conclusions:

• Ranolazine did not significantly decrease the incidence of the first VT, VF, or death in high-risk ICD patients.
• Ranolazine administration showed a significant reduction in recurrent VT or VF requiring ICD therapy, without increasing mortality.
• Further studies are needed to confirm these findings and explore the role of ranolazine in specific ICD patient populations.